Understanding cognitive deficits in alzheimer's disease based on neuroimaging findings

Trends in Cognitive Sciences

Volumn 17, Issue 10, 2013, Pages 510-516

  Braskie, Meredith N ^a   Thompson, Paul M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dementia; Executive function; Memory; Mild cognitive impairment; MRI; PET

Indexed keywords

ALZHEIMER'S DISEASE; COGNITIVE DEFICITS; COGNITIVE PERFORMANCE; DEMENTIA; EXECUTIVE FUNCTION; MILD COGNITIVE IMPAIRMENTS; NEURODEGENERATION; POSITRON EMISSION TOMOGRAPHY (PET);

DATA STORAGE EQUIPMENT; GLYCOPROTEINS; MAGNETIC RESONANCE IMAGING; NEUROIMAGING; POLYETHYLENE TEREPHTHALATES; POSITRON EMISSION TOMOGRAPHY;

NEURODEGENERATIVE DISEASES;

AMYLOID; FLUORODEOXYGLUCOSE; GLUCOSE; PITTSBURGH COMPOUND B;

AGE; ALZHEIMER DISEASE; ANTERIOR CINGULATE; BRAIN ATROPHY; BRAIN SIZE; CARDIOVASCULAR RISK; CEREBROSPINAL FLUID; COGNITION; COGNITIVE DEFECT; EDUCATION; EPISODIC MEMORY; EXECUTIVE FUNCTION; FRACTIONAL ANISOTROPY; FRONTAL LOBE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLUCOSE METABOLISM; GRAY MATTER; HIPPOCAMPUS; HUMAN; INTELLIGENCE; LATERAL BRAIN VENTRICLE; LEARNING; MEMORY DISORDER; NEOCORTEX; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROIMAGING; PHYSICAL ACTIVITY; POSITRON EMISSION TOMOGRAPHY; REVIEW; TEMPORAL CORTEX; TEMPORAL LOBE; WHITE MATTER; WHITE MATTER LESION;

DEMENTIA; EXECUTIVE FUNCTION; MEMORY; MILD COGNITIVE IMPAIRMENT; MRI; PET;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; BRAIN; COGNITION; HUMANS; NEUROIMAGING; POSITRON-EMISSION TOMOGRAPHY;

EID: 84884411990     PISSN: 13646613     EISSN: 1879307X     Source Type: Journal    
DOI: 10.1016/j.tics.2013.08.007     Document Type: Review

References (98)

1. Stonnington C.M., et al. Predicting clinical scores from magnetic resonance scans in Alzheimer's disease. Neuroimage 2010, 51:1405-1413.
2. Dickerson B.C., Wolk D.A. Dysexecutive versus amnesic phenotypes of very mild Alzheimer's disease are associated with distinct clinical, genetic and cortical thinning characteristics. J. Neurol. Neurosurg. Psychiatry 2011, 82:45-51.
3. Evans M.C., et al. Volume changes in Alzheimer's disease and mild cognitive impairment: cognitive associations. Eur. Radiol. 2010, 20:674-682.
4. Nho K., et al. Voxel and surface-based topography of memory and executive deficits in mild cognitive impairment and Alzheimer's disease. Brain Imaging Behav. 2012, 6:551-567.
5. Chang Y.L., et al. Level of executive function influences verbal memory in amnestic mild cognitive impairment and predicts prefrontal and posterior cingulate thickness. Cereb. Cortex 2010, 20:1305-1313.
6. Thompson P.M., Vinters H.V. Pathologic lesions in neurodegenerative diseases. The Molecular Biology of Neurodegenerative Diseases 2012, 1-40. Elsevier. D. Teplow (Ed.).
7. Jack C.R., et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013, 12:207-216.
8. Fjell A.M., Walhovd K.B. New tools for the study of Alzheimer's disease: what are biomarkers and morphometric markers teaching us?. Neuroscientist 2011, 17:592-605.
9. Braskie M.N., et al. Plaque and tangle imaging and cognition in normal aging and Alzheimer's disease. Neurobiol. Aging 2010, 31:1669-1678.
10. Chetelat G., et al. Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. Brain 2011, 134:798-807.
11. Mormino E.C., et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009, 132:1310-1323.
12. Bahar-Fuchs A., et al. Prediction of amyloid-beta pathology in amnestic mild cognitive impairment with neuropsychological tests. J. Alzheimers Dis. 2013, 33:451-462.
13. Oh H., et al. Effects of age and beta-amyloid on cognitive changes in normal elderly people. Neurobiol. Aging 2012, 33:2746-2755.
14. Rowe C.C., et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging 2010, 31:1275-1283.
15. Landau S.M., et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann. Neurol. 2012, 72:578-586.
16. Protas H.D., et al. Prediction of cognitive decline based on hemispheric cortical surface maps of FDDNP PET. Neuroimage 2012, 61:749-760.
17. 18F]FDG PET. Eur. J. Nucl. Med. Mol. Imaging 2012, 39:990-1000.
18. Ossenkoppele R., et al. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement. Brain 2012, 135:2115-2125.
19. Mathis C.A., et al. In vivo assessment of amyloid-beta deposition in nondemented very elderly subjects. Ann. Neurol. 2012, 73:751-761.
20. Storandt M., et al. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh Compound B: cognitive decline associated with Abeta deposition. Arch. Neurol. 2009, 66:1476-1481.
21. Dore V., et al. Cross-sectional and longitudinal analysis of the relationship between abeta deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. JAMA Neurol. 2013, 70:903-911.
22. Wirth M., et al. Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not beta-amyloid in cognitively normal older individuals. J. Neurosci. 2013, 33:5553-5563.
23. Wirth M., et al. The effect of amyloid beta on cognitive decline is modulated by neural integrity in cognitively normal elderly. Alzheimers Dement. 2013, 10.1016/j.jalz.2012.10.012.
24. Small G.W., et al. Prediction of cognitive decline by positron emission tomography of brain amyloid and tau. Arch. Neurol. 2012, 69:215-222.
25. Villemagne V.L., et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann. Neurol. 2011, 69:181-192.
26. Ewers M., et al. CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cereb. Cortex 2012, 22:1993-2004.
27. Jones R.N., et al. Aging, brain disease, and reserve: implications for delirium. Am. J. Geriatr. Psychiatry 2010, 18:117-127.
28. Chetelat G., et al. Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain 2010, 133:3349-3358.
29. Landau S.M., et al. Association of lifetime cognitive engagement and low beta-amyloid deposition. Arch. Neurol. 2012, 69:623-629.
30. Lo R.Y., Jagust W.J. Effect of cognitive reserve markers on Alzheimer pathologic progression. Alzheimer Dis. Assoc. Disord. 2013, 10.1097/WAD.0b013e3182900b2b.
31. Hommet C., et al. Review of cerebral microangiopathy and Alzheimer's disease: relation between white matter hyperintensities and microbleeds. Dement. Geriatr. Cogn. Disord. 2011, 32:367-378.
32. Provenzano F.A., et al. White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease?. JAMA Neurol. 2013, 70:455-461.
33. Carmichael O., et al. Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch. Neurol. 2010, 67:1370-1378.
34. Marra C., et al. Patterns of cognitive decline and rates of conversion to dementia in patients with degenerative and vascular forms of MCI. Curr. Alzheimer Res. 2011, 8:24-31.
35. Maillard P., et al. Coevolution of white matter hyperintensities and cognition in the elderly. Neurology 2012, 79:442-448.
36. van der Vlies A.E., et al. Associations between magnetic resonance imaging measures and neuropsychological impairment in early and late onset Alzheimer's disease. J. Alzheimers Dis. 2013, 35:169-178.
37. Lo R.Y., Jagust W.J. Vascular burden and Alzheimer disease pathologic progression. Neurology 2012, 79:1349-1355.
38. Landau S.M., et al. Comparing PET imaging and CSF measurements of A-beta. Ann. Neurol. 2013, 10.1002/ana.23908.
39. van Norden A.G., et al. Diffusion tensor imaging of the hippocampus and verbal memory performance: the RUN DMC study. Hum. Brain Mapp. 2012, 33:542-551.
40. den Heijer T., et al. Structural and diffusion MRI measures of the hippocampus and memory performance. Neuroimage 2012, 63:1782-1789.
41. Mielke M.M., et al. Fornix integrity and hippocampal volume predict memory decline and progression to Alzheimer's disease. Alzheimers Dement. 2012, 8:105-113.
42. Zhuang L., et al. Microstructural white matter changes, not hippocampal atrophy, detect early amnestic mild cognitive impairment. PLoS ONE 2013, 8:e58887.
43. Lee D.Y., et al. Sub-regional hippocampal injury is associated with fornix degeneration in Alzheimer's disease. Front. Aging Neurosci. 2012, 4:1.
44. Bartzokis G. Alzheimer's disease as homeostatic responses to age-related myelin breakdown. Neurobiol. Aging 2011, 32:1341-1347.
45. Apostolova L.G., et al. Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects. Neuroimage 2010, 51:488-499.
46. Braak H., Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol. Aging 1995, 16:271-278. discussion 278-284.
47. Bai F., et al. Aberrant hippocampal subregion networks associated with the classifications of aMCI subjects: a longitudinal resting-state study. PLoS ONE 2011, 6:e29288.
48. Glodzik L., et al. Phosphorylated tau 231, memory decline and medial temporal atrophy in normal elders. Neurobiol. Aging 2011, 32:2131-2141.
49. Leow A.D., et al. Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage 2009, 45:645-655.
50. McDonald C.R., et al. Relationship between regional atrophy rates and cognitive decline in mild cognitive impairment. Neurobiol. Aging 2012, 33:242-253.
51. Gutman B.A., et al. Maximizing power to track Alzheimer's disease and MCI progression by LDA-based weighting of longitudinal ventricular surface features. Neuroimage 2013, 70:386-401.
52. Chou Y.Y., et al. Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls. Neuroimage 2009, 46:394-410.
53. Andreasen N., et al. CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42. World J. Biol. Psychiatry 2003, 4:147-155.
54. Apostolova L.G., et al. Ventricular enlargement and its clinical correlates in the imaging cohort from the ADCS MCI donepezil/vitamin e study. Alzheimer Dis. Assoc. Disord. 2013, 27:174-181.
55. Johnson K.A., et al. Brain imaging in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012, 2:a006213.
56. Petersen R.C. Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurologia 2000, 15:93-101.
57. Ouchi Y., Kikuchi M. A review of the default mode network in aging and dementia based on molecular imaging. Rev. Neurosci. 2012, 23:263-268.
58. Sperling R.A., et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009, 63:178-188.
59. Braskie M.N., et al. Recent advances in imaging Alzheimer's disease. J. Alzheimers Dis. 2013, 33(Suppl. 1):S313-S327.
60. Wolk D.A., et al. Amyloid imaging in mild cognitive impairment subtypes. Ann. Neurol. 2009, 65:557-568.
61. Shoghi-Jadid K., et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am. J. Geriatr. Psychiatry 2002, 10:24-35.
62. Klunk W.E., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound B. Ann. Neurol. 2004, 55:306-319.
63. 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J. Nucl. Med. 2009, 50:1251-1259.
64. 18F-AV-45: a PET agent for Abeta plaques in the brain. J. Nucl. Med. 2009, 50:1887-1894.
65. 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008, 7:129-135.
66. Chetelat G. Reply: the amyloid cascade is not the only pathway to AD. Nat. Rev. Neurol. 2013, 9:356.
67. Murphy E.A., et al. Six-month atrophy in MTL structures is associated with subsequent memory decline in elderly controls. Neuroimage 2010, 53:1310-1317.
68. Smith C.D., et al. Structural brain alterations before mild cognitive impairment in ADNI: validation of volume loss in a predefined antero-temporal region. J. Alzheimers Dis. 2012, 31(Suppl. 3):S49-S58.
69. Dickerson B.C., Wolk D.A. MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology 2012, 78:84-90.
70. Chiang G.C., et al. Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes. Radiology 2011, 259:844-851.
71. Nettiksimmons J., et al. Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline. Neurobiol. Aging 2010, 31:1419-1428.
72. Aksu Y., et al. An MRI-derived definition of MCI-to-AD conversion for long-term, automatic prognosis of MCI patients. PLoS ONE 2011, 6:e25074.
73. Chincarini A., et al. Local MRI analysis approach in the diagnosis of early and prodromal Alzheimer's disease. Neuroimage 2011, 58:469-480.
74. Wee C.Y., et al. Prediction of Alzheimer's disease and mild cognitive impairment using cortical morphological patterns. Hum. Brain Mapp. 2012, 10.1002/hbm.22156.
75. Eskildsen S.F., et al. Prediction of Alzheimer's disease in subjects with mild cognitive impairment from the ADNI cohort using patterns of cortical thinning. Neuroimage 2013, 65:511-521.
76. Querbes O., et al. Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve. Brain 2009, 132:2036-2047.
77. Westman E., et al. AddNeuroMed and ADNI: similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America. Neuroimage 2011, 58:818-828.
78. Li Y., et al. Discriminant analysis of longitudinal cortical thickness changes in Alzheimer's disease using dynamic and network features. Neurobiol. Aging 2012, 33:427.
79. Shaffer J.L., et al. Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology 2013, 266:583-591.
80. Landau S.M., et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010, 75:230-238.
81. Zhang D., Shen D. Multi-modal multi-task learning for joint prediction of multiple regression and classification variables in Alzheimer's disease. Neuroimage 2012, 59:895-907.
82. Hinrichs C., et al. Predictive markers for AD in a multi-modality framework: an analysis of MCI progression in the ADNI population. Neuroimage 2011, 55:574-589.
83. Kohannim O., et al. Boosting power for clinical trials using classifiers based on multiple biomarkers. Neurobiol. Aging 2010, 31:1429-1442.
84. Kohannim O., et al. Multilocus genetic profiling to empower drug trials and predict brain atrophy. Neuroimage 2013, 2:827-835.
85. Rajagopalan, P. et al. TREM2 risk variant and loss of brain tissue. N. Engl. J. Med. (in press).
86. Yuan L., et al. Multi-source feature learning for joint analysis of incomplete multiple heterogeneous neuroimaging data. Neuroimage 2012, 61:622-632.
87. Jahanshad N., et al. Neuroimaging, nutrition, and iron-related genes. Cell. Mol. Life Sci. 2013, 10.1007/s00018-013-1369-2.
88. Erickson K.I., et al. Exercise training increases size of hippocampus and improves memory. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:3017-3022.
89. Chou Y.Y., et al. Ventricular maps in 804 ADNI subjects: correlations with CSF biomarkers and clinical decline. Neurobiol. Aging 2010, 31:1386-1400.
90. Bosch B., et al. Multiple DTI index analysis in normal aging, amnestic MCI and AD. Relationship with neuropsychological performance. Neurobiol. Aging 2012, 33:61-74.
91. Delano-Wood L., et al. Posterior cingulum white matter disruption and its associations with verbal memory and stroke risk in mild cognitive impairment. J. Alzheimers Dis. 2012, 29:589-603.
92. Braskie M.N., et al. Common Alzheimer's disease risk variant within the CLU gene affects white matter microstructure in young adults. J. Neurosci. 2011, 31:6764-6770.
93. Jahanshad N., et al. Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:4768-4773.
94. Braskie M.N., et al. Neuroimaging measures as endophenotypes in Alzheimer's disease. Int. J. Alzheimers Dis. 2011, 2011:490140.
95. Kerchner G.A., et al. Hippocampal CA1 apical neuropil atrophy and memory performance in Alzheimer's disease. Neuroimage 2012, 63:194-202.
96. Daianu M., et al. Breakdown of brain connectivity between normal aging and Alzheimer's disease: a structural k-core network analysis. Brain Connect. 2013, 3:407-422.
97. Wang J., et al. Disrupted functional brain connectome in individuals at risk for Alzheimer's disease. Biol. Psychiatry 2013, 73:472-481.
98. Reijmer Y.D., et al. Disruption of cerebral networks and cognitive impairment in Alzheimer disease. Neurology 2013, 80:1370-1377.